Literature DB >> 17020470

PTPN11 gene analysis in 74 Brazilian patients with Noonan syndrome or Noonan-like phenotype.

Débora R Bertola1, Alexandre C Pereira, Lílian Maria José Albano, Paulo S L De Oliveira, Chong A Kim, José Eduardo Krieger.   

Abstract

Mutations in the PTPN11 gene are known to cause a large fraction of the cases of Noonan syndrome. The objective of this study was to determine the PTPN11 gene mutation rate in a cohort of clinically well-characterized Brazilian patients with Noonan or Noonan-like syndromes and to study the genotype-phenotype correlation. Fifty probands with Noonan syndrome ascertained according to well-established diagnostic criteria, 3 with LEOPARD syndrome, 5 with Noonan-like/multiple giant cell lesion syndrome, and 3 with neurofibromatosis/ Noonan were enrolled in this study. Mutational analysis was performed using denaturing high-performance liquid chromatography (DHPLC) followed by sequencing of amplicons with an aberrant elution profile. We detected missense mutations in the PTPN11 gene in 21 probands with Noonan syndrome (42%), in all 3 patients with LEOPARD syndrome, and in 1 case with Noonan-like/multiple giant cell lesion syndrome. One patient with neurofibromatosis-Noonan syndrome had a mutation in both the PTPN11 and NF1 genes. The only anomalies that reached statistical significance when comparing probands with and without mutations were the hematological abnormalities. Our data confirms that Noonan syndrome is a genetically heterogeneous disorder, with mutations in the PTPN11 gene responsible for roughly 50% of the cases. A definitive genotype-phenotype correlation has not been established, but the T73I mutation seems to predispose to a myeloproliferative disorder. Regarding Noonan-like syndromes, mutation of the PTPN11 gene is the main causal factor in LEOPARD syndrome, and it also plays a role in neurofibromatosis-Noonan syndrome. Noonan- like/multiple giant cell lesion syndrome, part of the spectrum of Noonan syndrome, is also heterogeneous.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17020470     DOI: 10.1089/gte.2006.10.186

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  13 in total

1.  PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome.

Authors:  Jung Min Ko; Jae-Min Kim; Gu-Hwan Kim; Han-Wook Yoo
Journal:  J Hum Genet       Date:  2008-11-20       Impact factor: 3.172

2.  SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions.

Authors:  Claire Beneteau; Hélène Cavé; Anne Moncla; Nathalie Dorison; Arnold Munnich; Alain Verloes; Bruno Leheup
Journal:  Eur J Hum Genet       Date:  2009-04-08       Impact factor: 4.246

3.  Phenotypic spectrum of 80 Greek patients referred as Noonan syndrome and PTPN11 mutation analysis: the value of initial clinical assessment.

Authors:  Anna Papadopoulou; Michalis Issakidis; Evangelia Gole; Konstantina Kosma; Helen Fryssira; Andreas Fretzayas; Polyxeni Nicolaidou; Sophia Kitsiou-Tzeli
Journal:  Eur J Pediatr       Date:  2011-05-18       Impact factor: 3.183

4.  Congenital Chylothorax as the Initial Presentation of PTPN11-Associated Noonan Syndrome.

Authors:  Darius Ebrahimi-Fakhari; Eli Freiman; Monica H Wojcik; Katie Krone; Alicia Casey; Ariel S Winn; Amy E Roberts; Beth D Harper
Journal:  J Pediatr       Date:  2017-03-28       Impact factor: 4.406

5.  Clinical and Molecular Findings of Tunisian Patients with RASopathies.

Authors:  Rim Louati; N Bouayed Abdelmoula; Imen Trabelsi; Dorra Abid; Christina Lissewski; Najla Kharrat; Samir Kamoun; Martin Zenker; Tarek Rebai
Journal:  Mol Syndromol       Date:  2014-05-23

6.  Noonan syndrome in diverse populations.

Authors:  Paul Kruszka; Antonio R Porras; Yonit A Addissie; Angélica Moresco; Sofia Medrano; Gary T K Mok; Gordon K C Leung; Cedrik Tekendo-Ngongang; Annette Uwineza; Meow-Keong Thong; Premala Muthukumarasamy; Engela Honey; Ekanem N Ekure; Ogochukwu J Sokunbi; Nnenna Kalu; Kelly L Jones; Julie D Kaplan; Omar A Abdul-Rahman; Lisa M Vincent; Amber Love; Khadija Belhassan; Karim Ouldim; Ihssane El Bouchikhi; Anju Shukla; Katta M Girisha; Siddaramappa J Patil; Nirmala D Sirisena; Vajira H W Dissanayake; C Sampath Paththinige; Rupesh Mishra; Eva Klein-Zighelboim; Bertha E Gallardo Jugo; Miguel Chávez Pastor; Hugo H Abarca-Barriga; Steven A Skinner; Eloise J Prijoles; Eben Badoe; Ashleigh D Gill; Vorasuk Shotelersuk; Patroula Smpokou; Monisha S Kisling; Carlos R Ferreira; Leon Mutesa; Andre Megarbane; Antonie D Kline; Amy Kimball; Emmy Okello; Peter Lwabi; Twalib Aliku; Emmanuel Tenywa; Nonglak Boonchooduang; Pranoot Tanpaiboon; Antonio Richieri-Costa; Ambroise Wonkam; Brian H Y Chung; Roger E Stevenson; Marshall Summar; Kausik Mandal; Shubha R Phadke; María G Obregon; Marius G Linguraru; Maximilian Muenke
Journal:  Am J Med Genet A       Date:  2017-07-27       Impact factor: 2.802

7.  Further evidence of genetic heterogeneity in Costello syndrome: involvement of the KRAS gene.

Authors:  Débora Romeo Bertola; Alexandre Costa Pereira; Amanda Salem Brasil; Lilian Maria José Albano; Chong Ae Kim; José Eduardo Krieger
Journal:  J Hum Genet       Date:  2007-04-28       Impact factor: 3.172

8.  Age-dependent germline mosaicism of the most common noonan syndrome mutation shows the signature of germline selection.

Authors:  Song-Ro Yoon; Soo-Kung Choi; Jordan Eboreime; Bruce D Gelb; Peter Calabrese; Norman Arnheim
Journal:  Am J Hum Genet       Date:  2013-05-30       Impact factor: 11.025

9.  Mutation Spectrum and Phenotypic Features in Noonan Syndrome with PTPN11 Mutations: Definition of Two Novel Mutations.

Authors:  Tahir Atik; Ayca Aykut; Filiz Hazan; Huseyin Onay; Damla Goksen; Sukran Darcan; Ajlan Tukun; Ferda Ozkinay
Journal:  Indian J Pediatr       Date:  2016-01-28       Impact factor: 1.967

10.  PTPN11 mutation associated with aortic dilation and hypertrophic cardiomyopathy in a pediatric patient with Noonan syndrome.

Authors:  John L Jefferies; John W Belmont; Ricardo Pignatelli; Jeffrey A Towbin; William J Craigen
Journal:  Pediatr Cardiol       Date:  2009-10-01       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.